Previous Article | Next Article ![]()
Journal of Bacteriology, January 2004, p. 35-42, Vol. 186, No. 1
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.1.35-42.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Heather Seidle,1 Christopher T. Walsh,2 and Ronald Parry1*
Department of Chemistry, Rice University, Houston, Texas 77005,1 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 021152
Received 7 July 2003/ Accepted 1 October 2003
|
|
|---|
|
|
|---|
![]() View larger version (8K): [in a new window] |
FIG. 1. Structures of COR, norcoronatine, CFA, CMA, and norcoronamic acid (norCMA).
|
To begin to decipher the mechanism of CMA biosynthesis, we report here the initial characterization of CmaA, a protein encoded by the CMA region that appears to be a didomain protein containing an adenylation domain (A domain) and a thiolation domain (T domain). We found that CmaA catalyzes the adenylation of L-allo-isoleucine and the attachment of L-allo-isoleucine to the CmaA T domain. We postulate that the enzyme-bound L-allo-isoleucine serves as the substrate for the later stages of CMA biosynthesis.
|
|
|---|
Reagents. Unless indicated otherwise, all chemicals were purchased from Sigma Chemical Co. (St. Louis, Mo.). Restriction enzymes were obtained from NEB Life Technologies (Beverly, Mass.), and Pfu Turbo polymerase was purchased from Stratagene (La Jolla, Calif.). Protein concentrations were determined with the Advanced protein assay reagent from Cytoskeleton Inc. (Denver, Colo.) or with Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, Calif.).
DNA manipulations.
Agarose gel electrophoresis, restriction enzyme digestion, and purification of DNA fragments were performed by standard procedures (33). Plasmids were prepared by using a Qiaprep Spin miniprep kit (Qiagen, Chatsworth, Calif.). Electrocompetent P. syringae FF5 cells were prepared as described previously (12), and electroporation was conducted by using a Bio-Rad Gene Pulser II at 200
, 2.5 kV, and 25 µF. Creation of the Pseudomonas expression vectors pSFFLAG-CTC and pSFFLAG-MAC has been described previously (9). P. syringae strains harboring the FLAG-tagged expression vectors were selected by ampicillin resistance. The nucleotide sequences of all expression constructs were confirmed by sequencing to verify the absence of errors. Resequencing of the CMA region of PG4180 was carried out by primer walking by using pSAY10 (40) as the template and was performed by a commercial sequencing facility. Polyacrylamide gel electrophoresis (PAGE)-purified sequencing and PCR primers were synthesized by Sigma Genosys (The Woodlands, Tex.).
Protein manipulations. Native PAGE and sodium dodecyl sulfate (SDS)-PAGE were performed by using the separation and development units of the PhastSystem (Amersham Biosciences, Piscataway, N.J.) or by using the Mini-Protean II system (Bio-Rad Laboratories). SDS-PAGE protein molecular weight standards (broad range) were obtained from Bio-Rad Laboratories. Native PAGE molecular weight standards were created by combining chymotrypsinogen A (molecular mass, 25 kDa), albumin (67 kDa), aldolase (158 kDa), catalase (232 kDa), ferritin (440 kDa), and thyroglobulin (669 kDa), all of which were purchased from Amersham Biosciences.
Computational analyses. Primary sequence alignment was performed by using the Gene Inspector 1.5 software (Textco, Inc., West Lebanon, N.H.) run on a Macintosh computer. Basic local alignment search tool (BLAST) analyses were performed at the National Center for Biotechnology Information web site (http://www.ncbi.nlm.nih.gov/). The ScanProsite program, available at the Expasy web site (http://us.expasy.org/tools/scanprosite/), was used to scan the CmaA amino acid sequence for the presence of signature motifs. GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, Calif.) was used for nonlinear regression analysis of all enzyme assay data. Sequencher, version 4.1 (Gene Codes Corporation, Ann Arbor, Mich.), was used to compile DNA sequence data.
Cloning of CmaA. (i) FLAG-tagged proteins.
Two sets of PCR primer pairs were used to amplify the P. syringae pv. glycinea cmaA gene from plasmid pSAY10 (40). The first set (primer pair 1) consisted of CmaA-F-EcoRI (5'-TATGAATTCCATGACCTCCTACCATTCACAT-3'; restriction site is underlined) and CmaA-R-SmaI (5'-AACCCCGGGTCTCAGTCATTTCCATGTTGGCTCC-3'), and the second set (primer pair 2) consisted of CmaA-F-EcoRI and CmaA-RNS-SmaI (5'-AACCCCGGGTCGTCATTTCCATGTTGGCTCC-3'). The two sets of primer pairs resulted in a PCR product containing unique EcoRI and SmaI restriction sites (underlined) at the 5' and 3' ends, respectively. After high-fidelity PCR amplification with Pfu Turbo DNA polymerase and either primer pair 1 or primer pair 2, the
1.8-kb PCR product was purified with a Qiaquick PCR purification kit (Qiagen), digested with EcoRI and SmaI, and ligated into the multiple cloning site of EcoRI-SmaI-digested pSFFLAG-MAC (for the product of primer pair 1) or pSFFLAG-CTC (for the product of primer pair 2). The resulting constructs were electroporated into E. coli by using a Gene Pulser II electroporator (Bio-Rad Laboratories) according to the manufacturer's instructions. The transformants were confirmed by ampicillin selection, restriction mapping, and DNA sequencing and were designated pSFFLAG-MACcmaA and pSFFLAG-CTCcmaA. For overproduction of CmaA in Pseudomonas, the constructs were electroporated into P. syringae pv. syringae FF5, a COR nonproducer (36), and protein expression and purification were carried out as previously described (9).
(ii) His-tagged proteins. The P. syringae pv. tomato DC3000 cmaA gene was amplified from the genomic DNA of this strain, which is a known COR producer. DC3000 genomic DNA was prepared by using a Bactozol kit (Molecular Research Center, Inc., Cincinnati, Ohio). PCR amplification with primers cmaA-NdeI (5'-GGAATTCCATATGACCTCCTACCATTCA-3') and cmaA-EcoRI (5'-AAAAAAGAATTCTCAGTCATTTCCATGTTG-3') resulted in a product containing unique NdeI and EcoRI sites (underlined). The PCR product was purified as described above and ligated into the multiple cloning site of NdeI-EcoRI-digested vector pET28b (Novagen, Madison, Wis.). The constructs were transformed into E. coli as described above and were selected by kanamycin resistance. DNA sequencing confirmed the identity of the insert. For overproduction of CmaA in E. coli, this construct was transformed into E. coli BL21(DE3) along with plasmid pSU20-Sfp containing the gene encoding Sfp, a Bacillus subtilis phosphopantetheinyl transferase with broad substrate specificity (22). pSU20-Sfp was constructed by removal of the sfp gene, along with its promoter and ribosome binding site, from plasmid pUC8-Sfp (24) as an EcoRI-BamHI fragment and ligation of the fragment into plasmid pSU20 (1) digested with EcoRI and BamHI.
For overproduction of the His-tagged CmaA protein (His-CmaA), BL21(DE3) cells harboring the desired plasmids were grown in Luria-Bertani medium supplemented with 30 µg of kanamycin per ml and 34 µg of chloramphenicol per ml. One liter of medium was inoculated with 10 ml of an overnight starter culture and incubated at 25°C until an optical density at 595 nm of 0.55 was reached. Protein expression was then induced by addition of 100 µM isopropyl-ß-D-thiogalactopyranoside (IPTG), and cells were allowed to grow for an additional 15 h at 15°C. Cells were harvested by centrifugation (10 min at 6,000 x g) and resuspended in lysis buffer (25 mM Tris [pH 8], 500 mM NaCl, 10% glycerol) and lysed by two passages through a French press at 10,000 lb/in2. Cell extracts were clarified by centrifugation (30 min at 15,000 x g) and applied to nickel-nitrilotriacetic acid resin (1 ml of resin for 3 liters of culture) (Qiagen). Cell lysate was allowed to bind in batch to the resin for 2 h at 4°C and then was decanted into a column. The resin was washed with 15 column volumes of lysis buffer and then eluted with a step gradient of lysis buffer containing increasing amounts of imidazole (5, 30, 60, 100, and 500 mM). CmaA eluted in the 100 and 500 mM imidazole fractions. Fractions containing the desired protein were dialyzed against 25 mM Tris (pH 7.5)-200 mM NaCl-10% glycerol and frozen at -80°C.
A C-terminal His-tagged version of CmaA was also constructed by amplification of the gene with primers cmaA-NcoI (5'-AAAAAACCATGGATGACCTCCTACCATTCA-3'; restriction site is underlined) and cmaA-XhoI (5'-AAAAAACTCGAGCTCATTTCCATGTTGGCT-3'). The resulting product was ligated into NcoI-XhoI-digested pET28b. Selection, transformation, and protein expression were performed as described above.
ATP-32PPi exchange assays. ATP-PPi exchange reactions were carried out at 25°C in 100-µl mixtures that contained 75 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM tris-(2-carboxyethyl)phosphine (Molecular Probes, Eugene, Oreg.), 1 mM [32P]sodium pyrophosphate (5 Ci/mol; Dupont NEN, Boston, Mass.), 5 mM ATP, 0.2 nmol of FLAG-tagged CmaA protein (CmaA-FLAG) or 0.14 nmol of His-CmaA, and various concentrations of amino acid substrate. The reactions were initiated by addition of enzyme, were allowed to proceed for 10 min, and then were quenched by addition of a 1.6% activated charcoal-4.46% tetrasodium pyrophosphate-3.5% perchloric acid mixture in water. The charcoal was collected by either centrifugation or filtration, washed twice with a 4.46% tetrasodium pyrophosphate-3.5% perchloric acid solution, and then, if collected by centrifugation, resuspended in 0.5 ml of water, combined with liquid scintillation cocktail (ScintiVerse; Fisher Scientific, Pittsburgh, Pa.), and placed in a liquid scintillation counter. If filtration was used to collect the charcoal, the entire filter paper was placed directly into the scintillation vial after the wash step, mixed vigorously with scintillation cocktail, and counted. Each reaction was performed at least in duplicate. The amount of charcoal-bound radioactivity was converted into reaction velocity by using the specific activity of the 32PPi. A nonlinear regression fit of the plot of velocity versus substrate concentration provided the Vmax and Km values.
PPi release assay. PPi levels were measured by monitoring the appearance of NADH (at 340 nm) generated by a coupled, continuous spectrophotometric assay (8). Reactions were carried out at 25°C, and the reaction mixtures (500 µl) contained 1 M Tris-HCl (pH 8), 50 mM UDP-glucose (Sigma-Aldrich, St. Louis, Mo.), 50 mM glucose 1,6-bisphosphate (Sigma-Aldrich), 10 mM NAD+, 100 mM dithiothreitol, 5 mM EDTA, 100 mM ATP, 1 M MgCl2, 1 U of UDP-glucose pyrophosphorylase (Sigma-Aldrich), 5 U of phosphoglucomutase (Sigma-Aldrich), 8 U of glucose-6-phosphate dehydrogenase (Sigma-Aldrich), 0.2 nmol of CmaA, and various concentrations of amino acid substrate. The reactions were initiated by addition of CmaA and were monitored for 30 to 45 min with a Hewlett-Packard 8453 diode array spectrophotometer (Agilent Technologies, Palo Alto, Calif.). The spectrophotometer recorded data points every 20 s. Each assay was performed in duplicate. A linear reaction velocity was obtained by using a minimum of 30 colinear data points and an extinction coefficient of 6,220 M-1 cm-1 for NADH.
Aminoacylation of the T domain of CmaA by L-allo-isoleucine. Radioautographic studies were performed to examine the reaction of enzymatically generated L-allo-isoleucyl-AMP with the free thiol of the 4'-phosphopantetheine arm located within the T domain of CmaA. Reactions were performed at 25°C, and the reaction mixtures (40 µl) contained 100 mM Tris-HCl (pH 8), 10 mM MgCl2, 1 mM TCEP [tris-(2-carboxyethyl)phosphine], 5 mM ATP, 800 µM L-[G-3H]allo-isoleucine (generally tritiated; 320 Ci/mol; Moravek Biochemicals, Brea, Calif.), and 0.3 nmol of FLAG-CmaA or 0.14 nmol of His-CmaA. A control reaction, from which ATP was excluded, was also carried out. The reaction was initiated by addition of CmaA and was allowed to proceed for 30 min. The reaction was terminated by addition of 8 ml of 6x SDS sample buffer (280 mM Tris-HCl [pH 6.8], 10% SDS, 30% glycerol, 0.6 M dithiothreitol, 0.01% bromophenol blue) and boiling for 5 min. Samples were analyzed by electrophoresis with a SDS-10% PAGE gel. After electrophoresis, the gel was soaked in fixing solution (isopropanol-water-acetic acid, 25:65:10) for 30 min, soaked in Amplify reagent (Amersham Biosciences) for 30 min, vacuum dried (60°C for 1 h), and exposed to Kodak Biomax XR X-ray film (Eastman Kodak Company, Rochester, N.Y.) for 3 days at -80°C before the film was developed.
|
|
|---|
![]() View larger version (99K): [in a new window] |
FIG. 2. Alignment of CmaA amino acid sequences. A comparison of the CmaA sequence from P. syringae pv. glycinea with the CmaA sequence from P. syringae pv. tomato DC3000 indicates that these two sequences are 96% identical. The residues enclosed in the rectangle create an AMP-binding domain signature sequence, whereas the residues enclosed in the ellipses are common to a T domain, as determined by using the ScanProsite program at the Expasy web site. The arrow indicates the putative 4'-phosphopantetheine attachment site. The underlined residues are the residues that contribute to the specificity-conferring code of A domains in nonribosomal peptide synthetases. See the text for further discussion.
|
|
View larger version (5K): [in a new window] |
FIG. 3. Gene organization in the CMA region of the COR biosynthetic gene cluster of P. syringae pv. glycinea PG4180.
|
In an attempt to identify the substrate specificity of CmaA, key residues that comprise the A domain specificity-conferring code (5, 35) were examined (underlined residues in Fig. 2). Of the 10 residues that make up the specificity-conferring code, 7 are found in A domains that are specific for L-isoleucine, L-leucine, and L-valine. Both L-isoleucine and L-allo-isoleucine have been shown to be incorporated into CMA, but L-allo-isoleucine, whose specificity-conferring code has not been defined yet, is a much more efficient precursor (25). The timing of the epimerization of L-isoleucine to L-allo-isoleucine is currently unknown. By analogy with the conversion of L-allo-isoleucine into CMA, it appears that norcoronamic acid should be derived from L-valine. For these reasons, L-isoleucine, L-allo-isoleucine, and L-valine each appeared to be a potential substrate for CmaA.
Protein overexpression and visualization.
Two complementary approaches were taken to overexpress CmaA for substrate specificity assays. In one approach, the P. syringae pv. glycinea CmaA protein was expressed in P. syringae pv. syringae FF5, a Pseudomonas strain that lacks the COR gene cluster (36). Additionally, the P. syringae pv. tomato CmaA protein was overexpressed in E. coli. To generate the appropriate constructs, the cmaA gene was PCR amplified from P. syringae pv. glycinea and P. syringae pv. tomato, cloned into expression vectors that produced FLAG-tagged and His-tagged proteins, respectively, and transformed into the appropriate hosts. The soluble protein yields were compared with N-terminal and C-terminal tag locations, and a C-terminal FLAG-tagged protein and an N-terminal His-tagged protein were selected for subsequent functional assays. Figure 4A shows the SDS-PAGE results for the N-terminal His-CmaA and the C-terminal CmaA-FLAG. As shown in the Fig. 4, denatured CmaA-FLAG electrophoresed faster than expected, since the protein migrated at a molecular weight <66,000, whereas the predicted molecular weight is actually
68,000. Denatured His-CmaA electrophoresed at approximately the same position as CmaA-FLAG. Native PAGE of CmaA-FLAG indicated that the protein exists as a dimer (Fig. 4B).
![]() View larger version (86K): [in a new window] |
FIG. 4. PAGE analysis of affinity-tagged CmaA. (A) SDS-PAGE analysis. Denatured CmaA migrated at a molecular weight (MW) slightly less than the molecular weight (68,500) predicted from its amino acid sequence. (B) Native PAGE analysis. CmaA-FLAG appeared to migrate as a dimer.
|
L-Leucine, L-valine, and L-isoleucine were suggested to be possible substrates by examining the specificity-conferring code of CmaA. A series of qualitative assays with His-CmaA indicated that L-allo-isoleucine is the preferred substrate, and a small amount of activation was also observed with L-leucine, L-valine, or L-isoleucine (Fig. 5). Kinetic parameters for the four isoleucine diastereomers were measured (Table 1). A more detailed kinetic analysis was performed with the more active CmaA-FLAG.
![]() View larger version (14K): [in a new window] |
FIG. 5. Relative amino acid substrate activities as determined by using the ATP-PPi exchange assay and His-CmaA. The y axis indicates the ATP-PPi exchange activity for various amino acid substrates compared to the activity for L-allo-isoleucine. The curved line indicates that the data for L-allo-isoleucine, at a relative activity of 100%, are off the scale relative to the data for the other substrates.
|
|
View this table: [in a new window] |
TABLE 1. Kinetic parameters for CmaA-FLAG and His-CmaA as determined by the PPi exchange assay
|
PPi release assay. A continuous, spectrophotometric assay was also employed to determine the substrate specificity of CmaA (8). This assay measures the release of PPi by means of a coupled enzyme system in which PPi drives the reduction of NAD+ to NADH, a process that is conveniently monitored at 340 nm. Continuous release of PPi must be accompanied by the release of the aminoacyl-AMP derivative to regenerate the free A domain for catalysis of another reaction cycle. Thus, this assay is in effect a measure of the frequency of loss of the aminoacyl-AMP derivative from the A domain active site. Following adenylation, preferred amino acid substrates are expected to be held tightly by the enzyme, presumably to await transfer to the 4'-phosphopantetheine arm of the T domain. On the other hand, less preferred substrates have a tendency to leak from the adenylation site following the adenylation reaction. With this assay, therefore, highly preferred substrates should generate relatively small Km and kcat values (i.e., tight binding with little leakage), while the substrates that are less preferred should yield larger Km and kcat values.
Table 2 shows the kinetic values obtained in the PPi release assay when CmaA-FLAG was used in conjunction with various substrates. As observed with the PPi exchange assay (Table 1), the PPi release assay results illustrated the preference of CmaA for L-isoleucine over L-leucine and L-valine. Furthermore, the specificity of CmaA for L-isoleucine over D-isoleucine was also apparent when this assay was used. Most importantly, it is clear that L-allo-isoleucine was the most preferred substrate for CmaA of all the substrates tested, as it displayed the smallest Km and kcat values and the largest kcat/Km value (Table 2). These results are in good agreement with those of the PPi exchange assay.
|
View this table: [in a new window] |
TABLE 2. Kinetic parameters for CmaA-FLAG as determined by the forward PPi assay
|
![]() View larger version (28K): [in a new window] |
FIG. 6. Covalent labeling of CmaA-FLAG by L-[G-3H]allo-isoleucine in the presence of ATP.
|
|
|
|---|
Discrete A domain-T domain proteins in biosynthetic pathways often capture a proteogenic amino acid and modify it. The modified amino acid is then released to create a dedicated pool of nonproteinogenic monomers for natural product biosynthesis (7). For example, in the nikkomycin biosynthetic pathway, a discrete A domain-T domain enzyme specifically activates and loads histidine, after which a P450 enzyme hydroxylates the ß-carbon position of the covalently sequestered histidine residue. Similar discrete A domain-T domain proteins are observed in numerous other natural product pathways, such as those for chloramphenicol and novobiocin (7). In this study we demonstrated that the logic of CMA biosynthesis is to activate L-allo-isoleucine and to link it to CmaA in the form of a thiolester. It is postulated that the covalently linked L-allo-isoleucine is cyclized to produce covalently bound CMA, which is subsequently hydrolyzed by CmaT to produce free CMA.
The cmaA gene from P. syringae pv. glycinea PG4180 and the cmaA gene from P. syringae pv. tomato DC3000 were cloned and expressed in a Pseudomonas host strain and in E. coli, respectively, and were purified by affinity chromatography. The protein was posttranslationally modified in the T domain with a 4'-phosphopantetheinyl moiety in vivo, either by the heterologously expressed Bacillus phosphopantetheinyl transferase Sfp in the E. coli expression system or by an endogenous Pseudomonas transferase. The kinetic data indicate that the CmaA that is produced in Pseudomonas is substantially more active than the enzyme that is produced in E. coli. The N-terminally tagged version produced in E. coli has a mutation in the protein sequence (Ser521Phe) which may contribute to the decrease in activity. However, a wild-type C-terminally His-tagged construct also exhibited substantially reduced activity compared to the activity of the Pseudomonas protein (data not shown). Therefore, we suspect that the differences in the kinetic data are due to the fact that E. coli is a poor expression vehicle for the COR biosynthetic proteins. CmaA protein folding may not occur properly in E. coli, or alternatively, the B. subtilis phosphopantetheinyl transferase may not modify CmaA efficiently. Incubation of purified protein from either background with L-[G-3H]allo-isoleucine and subsequent analysis by SDS gel electrophoresis followed by autoradiography revealed that the protein was covalently modified with this amino acid in an ATP-dependent manner (Fig. 6). Monitoring 32PPi exchange data, which measured the enzyme-dependent reversible formation of an aminoacyl-AMP derivative, indicated that L-allo-isoleucine is strongly favored as the substrate over all the other amino acids examined. The data suggest that free L-allo-isoleucine is biosynthesized by the phytopathogenic P. syringae strains prior to this step of CMA biosynthesis. How this unusual isoleucine diastereomer is synthesized remains unknown. The kinetic parameters for L-valine indicate that it is a rather poor substrate. This is somewhat surprising given the natural occurrence of norcoronamic acid, which is probably derived from L-valine by a process similar to CMA formation. However, norcoronatine is a minor constituent of P. syringae pv. glycinea fermentation, and so formation of norcoronamic acid may be a relatively inefficient process.
The A domains of nonribosomal peptide synthetases typically exhibit a consensus sequence that determines the amino acid substrate specificity. While the consensus sequence of L-isoleucine-activating domains is very similar to that of CmaA (Fig. 2), there are three changes in the consensus sequence that may be responsible for the preference for L-allo-isoleucine. Although other L-allo-isoleucine-containing natural products exist (23, 34), this is the first example of an A domain specific for the (2S,3R) stereochemistry of L-allo-isoleucine.
In this paper we describe the first characterization of the CMA biosynthetic pathway at the enzymatic level. The data reveal that there is a discrete A domain-T domain whose function is to tether L-allo-isoleucine, presumably for subsequent cyclization and hydrolysis by CmaT to produce CMA. Previous studies have shown that CmaT exhibits thioesterase activity with model substrates (28). In addition to the CmaA and CmaT genes, five other genes are present in the CMA biosynthetic region of P. syringae PG4180 (Fig. 3). The sequence of CmaB exhibits similarities to the sequences of
-ketoglutarate-dependent dioxygenases, BarB1/Bar2 encoded by the barbamide gene cluster (6), and SyrB2 encoded by the syringomycin gene cluster (15, 41). These similarities suggest that CmaB is a nonheme iron dioxygenase that may carry out hydroxylation or chlorination of the CmaA-bound L-allo-isoleucine at C-6 (Fig. 7). CmaC exhibits similarity to methylmalonyl coenzyme A mutases, which suggests that its role may be to deprotonate and cyclize CmaA-bound 6-hydroxy-allo-isoleucine or 6-chloro-allo-isoleucine to produce CmaA-bound CMA (Fig. 7). CmaD exhibits similarities to acyl carrier proteins, while CmaE shows similarities to proteins with an
/ß hydrolase fold. The role played by these two proteins is unclear. Characterization of the later steps in the CMA biosynthetic pathway is under way.
![]() View larger version (10K): [in a new window] |
FIG. 7. Hypothetical biosynthetic pathway for conversion of L-allo-isoleucine into CMA.
|
Construction of vector pSU20-sfp by M. G. Thomas is also gratefully acknowledged.
Present address: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»